CRSP
Price
$52.98
Change
+$0.32 (+0.61%)
Updated
Sep 3 closing price
Capitalization
4.82B
55 days until earnings call
DNA
Price
$11.33
Change
+$0.31 (+2.81%)
Updated
Sep 3 closing price
Capitalization
670.73M
Interact to see
Advertisement

CRSP vs DNA

Header iconCRSP vs DNA Comparison
Open Charts CRSP vs DNABanner chart's image
CRISPR Therapeutics AG
Price$52.98
Change+$0.32 (+0.61%)
Volume$1.64M
Capitalization4.82B
Ginkgo Bioworks Holdings
Price$11.33
Change+$0.31 (+2.81%)
Volume$1.49M
Capitalization670.73M
CRSP vs DNA Comparison Chart in %
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. DNA commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and DNA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (CRSP: $52.66 vs. DNA: $11.02)
Brand notoriety: CRSP and DNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 47% vs. DNA: 164%
Market capitalization -- CRSP: $4.82B vs. DNA: $670.73M
CRSP [@Biotechnology] is valued at $4.82B. DNA’s [@Biotechnology] market capitalization is $670.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileDNA’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • DNA’s FA Score: 1 green, 4 red.
According to our system of comparison, DNA is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 2 TA indicator(s) are bullish while DNA’s TA Score has 2 bullish TA indicator(s).

  • CRSP’s TA Score: 2 bullish, 6 bearish.
  • DNA’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, DNA is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а -4.05% price change this week, while DNA (@Biotechnology) price change was -13.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +16.10%, and the average quarterly price growth was +32.67%.

Reported Earning Dates

CRSP is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.82B) has a higher market cap than DNA($671M). CRSP YTD gains are higher at: 33.791 vs. DNA (12.220). DNA has higher annual earnings (EBITDA): -292.97M vs. CRSP (-533.5M). CRSP has more cash in the bank: 1.72B vs. DNA (474M). CRSP has less debt than DNA: CRSP (215M) vs DNA (429M). DNA has higher revenues than CRSP: DNA (231M) vs CRSP (35M).
CRSPDNACRSP / DNA
Capitalization4.82B671M718%
EBITDA-533.5M-292.97M182%
Gain YTD33.79112.220277%
P/E RatioN/AN/A-
Revenue35M231M15%
Total Cash1.72B474M363%
Total Debt215M429M50%
FUNDAMENTALS RATINGS
CRSP: Fundamental Ratings
CRSP
OUTLOOK RATING
1..100
69
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
47
P/E GROWTH RATING
1..100
79
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CRSPDNA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 7 days ago
80%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 20 days ago
80%
Bullish Trend 13 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
83%
Bearish Trend 7 days ago
86%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TRLWX24.44-0.11
-0.45%
Nuveen Large Cap Value W
RYRHX56.48-0.33
-0.58%
Rydex Russell 2000 H
MUSEX39.88-0.26
-0.65%
MFS Blended Research Core Equity I
CMLIX50.91-0.37
-0.72%
Congress Large Cap Growth Institutional
TPLNX19.72-0.16
-0.80%
Timothy Plan Small Cap Value A

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with RXRX. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+1.60%
RXRX - CRSP
68%
Closely correlated
-0.85%
BEAM - CRSP
67%
Closely correlated
-0.31%
NTLA - CRSP
64%
Loosely correlated
+0.40%
CRBU - CRSP
59%
Loosely correlated
+0.53%
ABCL - CRSP
58%
Loosely correlated
-3.11%
More

DNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNA has been loosely correlated with RXRX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNA
1D Price
Change %
DNA100%
-13.02%
RXRX - DNA
53%
Loosely correlated
-0.85%
ABCL - DNA
49%
Loosely correlated
-3.11%
CRSP - DNA
49%
Loosely correlated
+1.60%
ABSI - DNA
48%
Loosely correlated
-2.09%
NTLA - DNA
48%
Loosely correlated
+0.40%
More